Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns-Reference-Cited by-同舟云学术

Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns

Published:2021-01-01 Issue:1 Volume:13 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Cunningham Orla¹,Scott Martin²,Zhou Zhaohui Sunny³,Finlay William J.J.¹

Affiliation:

1. UltraHuman Eight Limited, C/o Kreston Reeves Llp, Kent, UK

2. Department of Biopharm Discovery, GlaxoSmithKline Research & Development, Hertfordshire, UK

3. Department of Chemistry and Chemical Biology, Barnett Institute for Chemical and Biological Analysis, Northeastern University, Boston, Massachusetts, USA

Funder

The author(s) reported there is no funding associated with the work featured in this article

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2021.1999195

Reference70 articles.

1. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer

2. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics

3. Polyreactivity of antibody molecules

4. Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition

5. Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developability considerations for bispecific and multispecific antibodies;mAbs;2024-08-27

2. The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics;mAbs;2024-08-24

3. Neutralizing antibody against GDF15 for treatment of cancer-associated cachexia;PLOS ONE;2024-08-22

4. De novo generation of SARS-CoV-2 antibody CDRH3 with a pre-trained generative large language model;Nature Communications;2024-08-10

5. Changes in the Public IgM Repertoire and its Idiotypic Connectivity in Alzheimer’s Disease and Frontotemporal Dementia;2024-07-17